Racial differences of secondary metastasis in patients with colon cancer: A United States population-based cohort study.

Authors

null

Thanathip Suenghataiphorn

Griffin Hospital, Derby, CT

Thanathip Suenghataiphorn , Narathorn Kulthamrongsri , Narisara Tribuddharat , Pojsakorn Danpanichkul , Tuntanut Lohawatcharagul , Sakditad Saowapa , Jerapas Thongpiya , Natapat Chaisidhivej , Soravis Alm Osataphan

Organizations

Griffin Hospital, Derby, CT, Mayo Clinic, Pheonix, AZ, St. Elizabeth's Medical Center, Brighton, MA, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, Texas Tech University Health Sciences Center, Lubbock, TX, University of Nebraska Medical Center, Omaha, NE, Beth Israel Deaconess Medical Center, Boston, MA

Research Funding

No funding sources reported

Background: Disparities in health outcomes exist among racial and ethnic groups in the United States, notably in patients with colon cancer. Metastasis is the primary cause of cancer morbidity and mortality. However, data on the metastasis risks and clinical outcomes on hospitalized individuals with colon cancer is still limited. Therefore, we aim to assess the association between metastatic colon cancer and racial differences. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to explore patients who have colon cancer as the primary diagnosis. Additionally, we identified evidence of metastasis, as recorded by ICD-10-CM. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was racial differences in organ metastasis and secondary outcomes included mortality and length of stay. Statistical significance was established at p-value of 0.05. Results: We identified 80,130 patients with primary diagnosis of colon cancer at discharge. The mean age was 67.4 years; 49.7% were female. Caucasians accounted for 69.3%, with African Americans at 13.3% and Hispanics at 8.2%. 15% of the patients had liver metastasis, whereas 22% had lung metastasis. In a multivariate analysis adjusting for patient, COVID-19, chemotherapy usage and hospital factors, African Americans had higher risk of lung metastasis (aOR 1.22; 95%CI (1.07, 1.40), p = 0.003), higher risk of liver metastasis (aOR 1.51; 95%CI (1.31, 1.74), p = 0.021) and longer length of stay (b = 0.95; 95%CI (0.56, 1.33), p = 0.001). Hispanics also had higher risk of lung (aOR 1.22, p < 0.05) and liver metastasis (aOR 1.24, p = 0.021). We observed an increase in risk of metastasis and mortality but non-statistically significant in some parameters and races, as shown in table provided. Conclusions: In conclusion, our study revealed that racial difference is associated with higher risk of metastasis, as well as other outcomes. To establish a causal relationship between races, metastasis, and mortality in patients with colon cancer, further longitudinal research is necessary.

Adjusted odds ratio, adjusted for patient characteristics, hospital location and COVID-19 conditions.

RaceLung metastasisLiver metastasisMortalityLength of stay**
CaucasianBaseline
African American1.22 (1.07, 1.40)*1.51 (1.31, 1.74)*1.08 (0.77, 1.52)0.95 (0.56, 1.33)*
Hispanic1.18 (1.00, 1.40)*1.24 (1.03, 1.50)*1.02 (0.67, 1.56)0.16 (-0.27, 0.61)
Asian1.00 (0.77, 1.29)0.83 (0.61, 1.12)1.51 (0.82, 2.77)0.59 (-0.02, 1.21)
Native American1.00 (0.47, 2.13)1.18 (0.52, 2.68)N/A0.06 (-1.45, 1.59)
Others1.06 (0.82, 1.36)1.07 (0.80, 1.44)1.33 (0.70, 2.55)0.32 (-0.29, 0.93)

*Denotes statistically significant at p-level.

**Length of Stay is expressed as beta-coefficient N/A denotes no subpopulation group.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Real-World Evidence/Real-World Data

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 80)

DOI

10.1200/JCO.2024.42.23_suppl.80

Abstract #

80

Poster Bd #

F2

Abstract Disclosures

Similar Abstracts

First Author: Sameh Hany Emile

First Author: Edward Christopher Dee

Abstract

2024 ASCO Genitourinary Cancers Symposium

Evaluation of ctDNA in patients with mCRPC with liver metastases.

First Author: Minqi Huang